Severe reactivation of seronegative occult hepatitis B after chemotherapy for lymphoma.

Competing Interests: Declaration of interests HAT is and has been principal investigator for research grants from the National Cancer Institute, Gilead Sciences, and Merck & Co., Inc., with all funds paid to the MD Anderson Cancer Center. HAT is and has been a paid scientific advisor for AbbVie, Inc., Gilead Sciences, Merck & Co., Inc., and Dynavax Technologies; MD Anderson Cancer Center is managing the terms of these arrangements in accordance with its conflict-of-interest policies. All other co-authors declare no competing interests.